Page 1 of 1

TEMSO phase III study results for relapsing MS

Posted: Fri Oct 15, 2010 2:34 am
by MSUK
Image

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933